Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

Published on March 4, 2014 at 8:41 AM · No Comments

Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.

Marcy Graham, Ambit's Executive Director of Investor Relations, will provide an overview of the Company and its lead drug candidate, quizartinib, at 9:00 a.m. ET on Wednesday, March 12, 2014, followed by a breakout session at 9:30am.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available until April 1, 2014 following the initial presentation webcast. 

Source:

Ambit Biosciences

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients